Impact of hypertension on ventricular remodeling in patients with aortic stenosis

João Carlos Hueb1, João T R Vicentini, Meliza Goi Roscani

  • 1Hospital das Clínicas, Faculdade de Medicina de Botucatu-Unesp, Botucatu, SP, Brasil. jchueb@cardiol.br

Insights

Hypertension significantly increases left ventricular mass in patients with aortic stenosis (AS). It also influences ventricular geometry, particularly in severe AS cases, highlighting its role in cardiovascular risk.

Area of Science:

  • Cardiology
  • Echocardiography
  • Hypertension Research

Background:

  • Left ventricular hypertrophy (LVH) is a key indicator of cardiovascular risk.
  • LVH is commonly linked to arterial hypertension (AH) and aortic stenosis (AS), which can coexist.
  • The distinct impact of AH and AS on LVH when present together requires clarification.

Purpose of the Study:

  • To assess left ventricular hypertrophy (LVH) and ventricular geometry in patients with aortic stenosis (AS).
  • To specifically evaluate the influence of coexisting arterial hypertension (AH) on LVH and geometry in AS patients.

Main Methods:

  • Retrospective, observational, and transversal study of 298 patients with echocardiographic diagnosis of AS.
  • LVH defined by myocardial mass thresholds (men > 224 g, women > 162 g).
  • Patients categorized by AS severity (mild, moderate, severe) and presence/absence of hypertension.

Main Results:

  • Arterial hypertension (AH) was associated with significantly increased ventricular mass across all AS severity levels.
  • Hypertension increased the risk of developing LVH in patients with AS (OR = 2.1).
  • Hypertensive patients with severe AS showed a higher frequency of concentric hypertrophy compared to non-hypertensive counterparts.

Conclusions:

  • Arterial hypertension is an independent factor contributing to increased left ventricular mass in patients with aortic stenosis.
  • Hypertension significantly influences ventricular geometry, particularly leading to concentric hypertrophy in severe AS.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Aortic Regurgitation I: Introduction01:15

Aortic Regurgitation I: Introduction

IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...